Pieris Pharmaceuticals (PIRS) Receives New Coverage from Analysts at Robert W. Baird

Robert W. Baird started coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research report sent to investors on Monday morning, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $5.00 price objective on the biotechnology company’s stock.

PIRS has been the topic of a number of other reports. ValuEngine raised shares of Pieris Pharmaceuticals from a hold rating to a buy rating in a research report on Friday, April 5th. Zacks Investment Research raised shares of Pieris Pharmaceuticals from a hold rating to a buy rating and set a $3.75 target price on the stock in a research report on Saturday, April 13th. Cowen reissued a buy rating on shares of Pieris Pharmaceuticals in a research report on Monday. Finally, HC Wainwright reissued a buy rating and set a $5.00 target price on shares of Pieris Pharmaceuticals in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $5.08.

NASDAQ PIRS opened at $3.81 on Monday. Pieris Pharmaceuticals has a 52 week low of $2.39 and a 52 week high of $6.55. The firm has a market cap of $174.49 million, a PE ratio of -7.62 and a beta of 1.78.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its earnings results on Monday, March 18th. The biotechnology company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.05). Pieris Pharmaceuticals had a negative return on equity of 64.64% and a negative net margin of 84.75%. The firm had revenue of $4.91 million for the quarter, compared to analyst estimates of $6.92 million. Research analysts anticipate that Pieris Pharmaceuticals will post -0.81 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA acquired a new stake in shares of Pieris Pharmaceuticals during the first quarter worth $36,000. SG Americas Securities LLC acquired a new stake in shares of Pieris Pharmaceuticals during the fourth quarter worth $36,000. Prudential Financial Inc. acquired a new stake in shares of Pieris Pharmaceuticals during the fourth quarter worth $43,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Pieris Pharmaceuticals during the first quarter worth $57,000. Finally, Alambic Investment Management L.P. acquired a new stake in shares of Pieris Pharmaceuticals during the fourth quarter worth $59,000. 69.76% of the stock is currently owned by hedge funds and other institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Story: Do Tariffs Work?

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.